论文部分内容阅读
一些环氧化酶-2抑制剂(COX-2抑制剂)已经在很多国家被撤出市场。由于顾虑潜在的心血管不良反应,很多同类药物在临床中的使用也受到很大限制。正如 Kearney 和其同事所指出的(见本期第276页):这种担心是必要的,因为与安慰剂或者其他非甾体抗炎药(NSAIDs)相比,长期使用 COX-2抑制剂可以增加心肌梗死的危险性。COX-2抑制剂撤出市场或限制使用是不是让我们失去了一个更好的治疗选择呢?可能不是的。尽管 COX-2抑制剂具有良好的胃肠道安全性,发生胃肠道溃疡的几率较低,但是有充分的证据表明其他
Some COX-2 inhibitors (COX-2 inhibitors) have been withdrawn from the market in many countries. Due to concerns about potential adverse cardiovascular events, the use of many of the same drugs in the clinic is also severely limited. As Kearney and colleagues point out (see page 276 of this issue): This concern is necessary because long-term use of COX-2 inhibitors compared to placebo or other non-steroidal anti-inflammatory drugs (NSAIDs) Increase the risk of myocardial infarction. Cumulative withdrawal of COX-2 inhibitors from the market or restricted use may have caused us to lose a better treatment option. Probably not. Although COX-2 inhibitors have good gastrointestinal safety and low incidence of gastrointestinal ulcers, there is good evidence that other